Hilary Butler:

On page 435 of the Senate Hearing S.3419 held on April 20, 21 and May 3, 4, 1972 is a chart, exactly as below:

[1972] VACCINES REFERRED TO AS INEFFECTIVE BY THE DBS DIRECTOR AND THEIR MANUFACTURERS.

Product listed in report Brand name of product listed in report Manufacturer

  1. Product A ……………..Bacterial vaccine mixed respiratory………………….Hollister-Stier Laboratories.
  2. Product B………………Respiratory UBA……………………………………….Eli Lilly & Co.
  3. Product C……………...Staphylococcus-streptocuccus UBA……………………….Do
  4. Product D…………..….Combined vacine No. 4 with catarrhhalis………………….Do
  5. Product E………….…..Mixed vaccine No. 4 with H. Influenzae…………………...Do
  6. Product F………….…..Staphylococcus vaccine …………………………………….Do
  7. Product G……………..Entoral………………………………………………………….Do
  8. Product H……………..typhoid H antigen………………………………………………Do
  9. Product I……………….Vacagen tablets………………………………………...Merck, Sharp & Dohme.
  10. Product J………………Brucellin antigen……………………………………………….Do
  11. Product K………………Staphylo-strepto serobacterin vaccine………………………Do
  12. Product L………………Catarrhalis serobacterin vaccine mixed………………………Do
  13. Product M……………...Sensitized bacterial vaccine H. influenzae………………….Do

    14. Serobacterin in vaccine mixed.

  14. Product N……………….Staphage lysate type I………………………………Delmont Laboratories, Inc.
  15. Product O……………….Staphage lysate type III……………………………………….Do
  16. Product P………………..Staphage lysate types I and III………………………………Do.
  17. Product Q………………..Catarrhalis combined vaccine……………….Merrell-National laboratories

    18. (division, Richardson-Merrell)

  18. Product R……………..…Strepto-staphylo vatox………………………..Merrell-National Laboratories
  19. Product S………………..Staphylococcus toxoid-vaccine vatox ……………………...Do
  20. Product T……………..…Respiratory vatox…………………………..………………….Do
  21. Product U……………..…Respiratory B.A.C…………………………………Hoffman Laboratories, Inc.
  22. Product V………………..Gram-negative B.A.C……………………….………………..Do
  23. Product W…………….....Pooled stock B.A.C. No 1 …………………..………………Do
  24. Product X…………………Pooled stock B.A.C. No 2………………….……………….Do
  25. Product Y…………………Staphylococcal B.A.C……………………………………….Do
  26. Product Z………………….Pooled skin B.A.C…………………..………………………Do
  27. Product AA………………..Mixed infection phylacogen …………………….Parke, Davis & Co
  28. Product BB………….…….Immunovac oral vaccine……………………………………Do
  29. Product CC………….…….Immunovac respiratory vaccine (parenteral)……………..Do.
  30. Product DD……………….Streptococcus immunogen arthritis. ………………………Do
  31. Product EE………………..N. catarrhalis vaccine (combined)…………………………Do
  32. Product FF………………..No catarrhalis vaccine immunogen (combined)………….Do

--------------------------------------------------------------------------------------------------------------------------------------------

Just above a heading WORTHLESS VACCINES on page 346, reads:

 

"SENATOR PERCY. Doctor, right at the outset of your testimony, you make reference to the General Accounting Office report, that 32 vaccines of no known value, and some possible harm, have continued to be licensed. I have never seen a figure as to what the total dollar value of those vaccines would be. What was the cost of the vaccines which were either of little value or perhaps even harmful, and which were administered to people who felt they were being protected?

Below the heading reads:

 

DR ISACSON. Well, I think it must be astronomical. I do not think I could give you an actual figure. Since some of these appear from the investigation to have been on the market for 20 years, certainly it must add up.

SENATORY PERCY. But we are talking about a cost investment of hundreds of milions of dollars, maybe…. We are locking the barn now after the horse has gone out."